arrow
B

Brendan M. Weiss

University of Alabama Birmingham
H指数:45
被引数:1.7万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Preclinical Proof-of-Concept of a Novel mRNA-Based Therapeutic Combination of an FcRH5 Targeted NK Cell Engager and an IL-15 Superagonist for the Treatment of Multiple Myeloma

基于mRNA的新型FcRH5靶向NK细胞衔接器与IL-15超激动剂组合疗法治疗多发性骨髓瘤的体外概念验证研究

BLOOD
IF23.1
2024-11-050
PRE
Preclinical Proof-of-Concept of an mRNA-Based T Cell Engager Targeting BCMA, FcRH5, and GPRC5D for the Treatment of Multiple Myeloma

针对BCMA、FcRH5和GPRC5D的mRNA基T细胞 engager在多发性骨髓瘤治疗中的临床前概念验证

BLOOD
IF23.1
2024-11-050
PRE
Feasibility and Implementation of the ASH Research Collaborative's COVID-19 Outcomes in Myeloma and the Impact of Vaccines (COSMIC): A Decentralized, Real-World Evidence Study for Patients with Multiple Myeloma to Monitor Outcomes Related to COVID-19 Vaccines and Infections

ASH Research Collaborative关于浆细胞瘤患者COVID-19结局及疫苗影响(COSMIC)的可行性研究与实施:一项针对多发性骨髓瘤患者、用于监测与COVID-19疫苗及感染相关结局的去中心化、真实世界证据研究

BLOOD
IF23.1
2024-11-050
PRE
Daratumumab plus bortezomib, cyclophosphamide, and dexamethasone in Asian patients with newly diagnosed AL amyloidosis: subgroup analysis of ANDROMEDA

Daratumumab联合硼替佐米,环磷酰胺和地塞米松在亚洲新诊断的AL淀粉样变性患者中的应用: 仙女座的亚组分析

2023-03-027
OAAI
Health-related quality of life in patients with light chain amyloidosis treated with bortezomib, cyclophosphamide, and dexamethasone +/- daratumumab: Results from the ANDROMEDA study

硼替佐米,环磷酰胺和地塞米松/- daratumumab治疗的轻链淀粉样变性患者的健康相关生活质量: ANDROMEDA研究的结果

2022-03-305
PRE
Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis

基于Daratumumab的免疫球蛋白轻链淀粉样变性的治疗

2021-07-01335
OA
International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM)

阴燃多发性骨髓瘤 (SMM) 的国际骨髓瘤工作组风险分层模型

2020-10-16146
OAAI
B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma
2019-04-29571
OA
Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma (vol 3, e120505, 2018)
2019-02-2143
OA
The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group (vol 15, pg 45, 2018)
2018-12-197
OAAI
The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group
2018-12-03349
OAAI
Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma
2018-04-19133
OAAI
Second primary malignancies in multiple myeloma: an overview and IMWG consensus

多发性骨髓瘤的第二原发恶性肿瘤: 概述和IMWG共识

2017-02-01105
OAAI